Donepezil

SKU: orb1300120

Description

Donepezil is a selective, reversible acetylcholinesterase inhibitor of the piperidine class. It is widely used in neuroscience research to study cholinergic neurotransmission and is a standard therapeutic agent in models of Alzheimer's disease, both in vitro and in vivo.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 120014-06-4
• MW: 379.49
• Purity: 99.69% (May vary between batches)
• Formula: C₂₄H₂₉NO₃
• SMILES: O=C1C=2C(=CC(OC)=C(OC)C2)CC1CC3CCN(CC4=CC=CC=C4)CC3
• Target: Cholinesterase (ChE)
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.27 mM);DMSO:97 mg/mL (255.61 mM)

Bioactivity

• Target IC50:
  AChE (human):11.6 nM|AChE (bovine):8.12 nM
• In Vivo:
  In plasma, urine, and bile, most donepezil metabolites are O-glucuronides. After oral ingestion, peak plasma concentrations are achieved in 3-5 hours and its absorption is not affected by food. Donepezil is slowly absorbed from the gastrointestinal tract and has a terminal elimination half-life of 50-70 hours in young volunteers (>100 hours in elderly subjects). After extensive metabolization in the liver, the parent compound is 93% bound to plasma proteins. Donepezil is metabolized in the liver via the cytochrome P450 system (CYP1A2-, CYP2D6-, CYP3A4-related enzymes). In animals, donepezil is found unchanged in the brain, and no metabolites are detected in the nervous tissue. Donepezil has linear pharmacokinetics over a dose range of 1-10 mg/day. 96% of circulating donepezil is protein bound .
  Read more...
• In Vitro:
  Donepezil has 500-1000-fold more selective for AChE over butyrylcholinesterase (BuChE). Short- and long-exposure of SH-SY5Y human neuroblastoma cells to donepezil induces a concentration-dependent inhibition of cell proliferation unrelated to muscarinic or nicotinic receptor blockade or apoptosis. Donepezil reduces the number of cells in the S-G2/M phases of the cell cycle, increases the G0/G1 population, and reduces the expression of two cyclins of the G1/S and G2/M transitions, cyclin E and cyclin B, in parallel with an increase in the expression of the cell cycle inhibitor p21. In addition, donepezil increases action potential-dependent dopamine release and modulates nicotinic receptors of substantia nigra dopaminergic neurons.
  Read more...
• Cell Research:
  Cell lines: retinal ganglion cells (RGCs). Concentrations: 0.1-10 μM. Incubation Time: 3 days. RGC survival after exposure to each reagent (glutamate, donepezil, tacrine, galanthamine, and HA14-1) is measured by calcein-AM staining after 3 days in culture, Briefly, cells are incubated in 1 μM calcein-AM in PBS for 15 minutes at 37℃. After the medium is replaced with fresh PBS, cells are examined under a fluorescence microscope using a fluorescein filter. The total number of surviving RGCs defined as cells with a calcein-AM stained cell body and a process extending at least two cell diameters from the cell body is counted in each well. The number of surviving RGCs without any drug served as a control.
  Read more...
• Animal Research:
  Animal Models: male C57BL/6 wild-type and CGRP( / ) mice (10-12 weeks old, 21–24 g). Formulation: added to the food powder. Dosages: 1.5 mg/kg (i.g.)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cholinesterase (ChE), Donepezil, Donepezilo, E 2020, E2020, E-2020, Aricept, bAChE, AChE, inhibit, Inhibitor, hAChE

Compound Identifiers

PubChem CID

3152